Relapsed Refractory Acute Lymphoblastic Leukemia clinical trials

Explore recruiting relapsed refractory acute lymphoblastic leukemia clinical trials.

Recruiting relapsed refractory acute lymphoblastic leukemia studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Relapsed Refractory Acute Lymphoblastic Leukemia trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

CART19 cells effects in patients with relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma.

Czechia

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A phase I/II study of Inotuzumab Ozogamicin as a single agent and in combination with chemotherapy for pediatric CD22-positive relapsed/refractory Acute Lymphoblastic Leukemia

Ireland, Belgium, Spain, Sweden, Finland, Netherlands +7 more

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Relapsed Refractory Acute Lymphoblastic Leukemia trials by city

Relapsed Refractory Acute Lymphoblastic Leukemia clinical trials

Recruiting relapsed refractory acute lymphoblastic leukemia studies right now

Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma

A Study of Revumenib and Mezigdomide in People With Leukemia

Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma

Clinical Study of Hospital-manufactured CD19 CAR-T in Children and Adolescents With Acute Lymphoblastic Leukemia

Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR

KSV01 Injection as the Therapy for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies

UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL

The Safety and Efficacy of RD06-03 CART Cell Injection in Patients With R/R Acute B-lymphoblastic Leukemia

CAR T Cells in the Treatment of Refractory and Relapsed CD19+ B Cell Neoplasms

Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

Also recruiting in Europe

CART19 cells effects in patients with relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma.

A phase I/II study of Inotuzumab Ozogamicin as a single agent and in combination with chemotherapy for pediatric CD22-positive relapsed/refractory Acute Lymphoblastic Leukemia

Relapsed Refractory Acute Lymphoblastic Leukemia trials by city

Other conditions